The China National Medical Products Administration has approved AstraZeneca's (AZN, Financial) new drug, AZD6234, for clinical trials. This peptide-based medication is designed for long-term weight management in overweight or obese adults with at least one obesity-related condition. AZD6234 is a long-acting amylin receptor agonist intended for weekly subcutaneous injection.
Currently in phase 2b clinical trials globally, AZD6234 aims to serve as an alternative treatment for obesity patients with intolerance to incretin-based therapies. Amylin, a hormone distinct from the GLP-1 signaling pathway, plays a role in hunger and satiety, helping to reduce energy intake and regulate glucose by working alongside insulin. Research suggests that amylin receptor agonists can aid weight loss by reducing fat mass while preserving lean mass and may work synergistically with GLP-1 receptor agonists.
